Navigation Links
KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
Date:2/23/2009

DEERFIELD, Ill., Feb. 23 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that KAPIDEX(TM) (dexlansoprazole) delayed release capsules are now available in pharmacies across the U.S. KAPIDEX, available in 30 mg and 60 mg doses, was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

KAPIDEX is the first proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. PPIs work by turning off many of the acid pumps in the stomach. KAPIDEX contains two types of enteric-coated granules resulting in a concentration-time profile with two distinct peaks: the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. In addition, KAPIDEX can be taken regardless of when food is consumed.

GERD is a chronic condition commonly known as acid reflux disease. GERD affects nearly 19 million Americans and is often characterized by frequent and persistent heartburn that occurs two or more days a week despite treatment and diet changes. GERD can affect both men and women, and symptoms are often triggered by certain foods, stress or pressure on the stomach.

About KAPIDEX (dexlansoprazole) delayed release capsules

KAPIDEX (dexlansoprazole) delayed release capsules, previously known by the development code TAK-390MR, is a proton pump inhibitor (PPI), which decreases acid production by turning off many of the acid pumps in the stomach, thus helping to protect the esophagus from acidic reflux so that esophageal inflammation can heal. KAPIDEX combines an enantiomer of lansoprazole with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication. KAPIDEX, taken once-daily, is approved for the healing of all grades of erosive esophagitis (EE) for up to eight weeks, maintaining healing of EE for up to six months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information

KAPIDEX is contraindicated in patients with known hypersensitivity to any component of the formulation. Symptomatic response with KAPIDEX does not preclude the presence of gastric malignancy. The most commonly reported treatment-emergent adverse reactions (greater than or equal to 2%): diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence. KAPIDEX should not be co-administered with atazanavir. KAPIDEX may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time.

Please see the complete prescribing information and visit the KAPIDEX Web site at www.kapidex.com.

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, oncology, gastroenterology, neurology, rheumatology and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about these Takeda companies, visit www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. KV Pharmaceuticals Launch of Gestiva(TM) Delayed
2. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
3. SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed
4. Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
5. Heart Attack Care Often Delayed for the Poor
6. Womens Alcohol Use Tied to Delayed Childbearing
7. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
8. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
9. Watson Launches Omeprazole Delayed-Release Capsules, 40MG
10. Delayed Sleep Pattern Tied to Irregular Menstrual Cycles
11. Teens Sleep Longer With Delayed School Starts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Indiana Fiber Network, LLC (IFN), the ... IFN as a fiber transport provider. IFN provided Lake City Bank with network ... , “IFN provides fiber transport to Lake City Bank, which includes ...
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot on ... CIOReview. , In a deliberate session with the honorary industrial experts, a list of ... with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample Management ...
(Date:5/25/2016)... ... May 25, 2016 , ... DKT International, ... the developing world, is pleased to release their 2015 global impact data. In ... pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe abortions across 21 countries ...
(Date:5/25/2016)... Puerto Vallarta, Mexico (PRWEB) , ... May 25, 2016 , ... ... menu surrounding the restorative properties of precious stones to complement its new wellness ... spread over two floors and feature a plethora of special services and insuite amenities, ...
(Date:5/25/2016)... ... ... For more than fifty years, we've suffered whiplash as each new scientific study seemed to ... latest nutritional advice – advice that was supposed to keep us healthy and slim. And ... adults are considered to be overweight and more than 1 in 3 adults are considered ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
(Date:5/24/2016)... , May 24, 2016 ... solutions for the healthcare sector, has been named the Coretex ... Hi-Tech Awards 2016. Dr Bruce Davey , ... for our team.  It,s really good to be recognised for ... internationally. Our products are used in 35 countries around the ...
Breaking Medicine Technology: